BeiGene (FRA:49BA) EV-to-Revenue

: 4.71 (As of Today)

View and export this data going back to 2016. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, BeiGene's enterprise value is €10,751 Mil. BeiGene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €2,282 Mil. Therefore, BeiGene's EV-to-Revenue for today is 4.71.

The historical rank and industry rank for BeiGene's EV-to-Revenue or its related term are showing as below:

FRA:49BA' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.67 Med: 25.53 Max: 9065.99
Current: 5.05

During the past 11 years, the highest EV-to-Revenue of BeiGene was 9065.99. The lowest was 4.67. And the median was 25.53.

FRA:49BA's EV-to-Revenue is ranked better than
59.75% of 1031 companies
in the Biotechnology industry
Industry Median: 7.58 vs FRA:49BA: 5.05

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), BeiGene's stock price is €123.00. BeiGene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €21.70. Therefore, BeiGene's PS Ratio for today is 5.67.

BeiGene EV-to-Revenue Historical Data

The historical data trend for BeiGene's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

22.25

63.39

18.61

13.42

6.76

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																13.42	12.40	8.86	7.32	6.76

Competitive Comparison

For the Biotechnology subindustry, BeiGene's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, BeiGene's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where BeiGene's EV-to-Revenue falls into.

BeiGene EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

BeiGene's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	10750.900	/	2281.511
	=	4.71

BeiGene's current Enterprise Value is €10,751 Mil.
BeiGene's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,282 Mil.

BeiGene (FRA:49BA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

BeiGene's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	123.00	/	21.701
	=	5.67

BeiGene's share price for today is €123.00.
BeiGene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.70.

BeiGene EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of BeiGene's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines